Diazabicyclooctanes (DBOs) are promising b-lactamase inhibitors. Some, including nacubactam (OP0595/RG6080), also bind PBP2 and have an enhancer effect, allowing activity against Enterobacteriaceae with MBLs, which DBOs do not inhibit. We tested the activity of nacubactam/b-lactam combinations against MBL-producing Enterobacteriaceae.
Introduction
Diazabicyclooctanes (DBOs) are potent non-b-lactam inhibitors of b-lactamases. 1 Avibactam is the sole analogue so far licensed, and is partnered with ceftazidime. It is also in Phase III trials combined with aztreonam. Four further DBOs have progressed into clinical development: ETX2514 (Entasis); 2 nacubactam (RG6080/OP0595; Roche, Fedora, Meiji); 3 relebactam (MK-7655; Merck); 4 and zidebactam (WCK5107; Wockhardt). 5 DBOs inhibit most or all class A and C b-lactamases, while activity against class D b-lactamases varies with the particular enzyme and inhibitor. [1] [2] [3] [4] [5] Although DBOs do not inhibit MBLs (class B b-lactamases), which are an expanding problem worldwide, 6 this limitation may be overcome in either of two ways. First, as with aztreonam/avibactam, the DBO can be combined with a monobactam, as these are stable to MBLs and need only to be protected from any co-produced ESBL or AmpC enzyme(s). 7, 8 Alternatively, several developmental DBOs, notably nacubactam, ETX2514 and zidebactam, have significant affinity for PBP2 of many Gramnegative species. 3, 5, 9, 10 This allows them to exert both a direct antibacterial effect and, like mecillinam (which also targets PBP2), an 'enhancer' mechanism, potentiating partner b-lactams that bind to PBP3. This combination of direct and enhancer-based activity means that combinations of MBL-labile b-lactams with nacubactam, ETX2514 or zidebactam can retain activity against MBL-producing Enterobacteriaceae 3, 5, 9 (also Pseudomonas ). Although the antibacterial activity of these DBOs is vulnerable to high-frequency mutational resistance the enhancer effect is often retained against DBOresistant mutants. 3, 5, 9, 11, 12 We assessed the activity of nacubactam combinations against MBL producers by testing against isolates sent to the UK reference laboratory. 
Materials and methods

Isolates
Susceptibility testing
MICs were determined by CLSI agar dilution 15 using Mueller-Hinton medium from Oxoid/ThermoFisher (Basingstoke, Hants, UK). When endpoints trailed, the growth of 4 colonies was counted as significant. Aztreonam, cefepime and meropenem were tested, as doubling dilutions, with nacubactam at 0, 1, 2 and 4 mg/L or with avibactam at 4 mg/L. 'Synergy' was defined as 3 doubling dilution reduction in the partner b-lactam MIC in the presence of the DBO.
Results and discussion
Behaviour of nacubactam alone
MIC distributions of nacubactam alone for the Combined Collection (i.e. the Consecutive and Supplementary Collections combined, n"309) are shown in Table 1 . Values for Proteeae were almost all .32 mg/L, whereas those for other genera were bimodal, with peaks at 1-8 and .32 mg/L. MICs for most (.88%) Escherichia coli and Enterobacter spp. fell into the lower peak, with few high values; those for Klebsiella spp. were widely scattered and complicated by trailing endpoints, but mostly fell into the higher peak, with 84 of 157 values .32 mg/L. MICs of avibactam alone, which was included as a control, were 4 mg/L for just 3 of 309 isolates (1%), with values .4 mg/L for the remaining 99%.
Analysis of the behaviour of nacubactam in combination
Depicting the MIC distributions for combinations of triple-action DBOs (i.e. those with direct antibacterial and enhancer effects as well as acting as b-lactamase inhibitors) is challenging. If MICs are expressed relative to the b-lactam, as is conventional for the b-lactam/b-lactamase inhibitor combinations, values can be low, either (i) because the DBO potentiates the b-lactam, or (ii) because the isolate is inhibited by the DBO itself. In addition, a distinction must be drawn between the behaviour of combinations involving cefepime and meropenem, which are MBL-labile, and those involving aztreonam, which is stable to MBLs. For combinations incorporating cefepime or meropenem, a low MIC requires either antibacterial activity by the DBO or a strong enhancer effect, whereas a low MIC for aztreonam combinations may be achieved solely by inhibition of other co-produced b-lactamases. MBL producers lacking ESBL or AmpC activity are anyway susceptible to aztreonam.
To capture these nuances, two presentations are provided. First, in Table 2 , conventional MIC distributions are shown for the Combined and Consecutive Collections and for various subsets. These are compared with the MIC distributions for the unprotected b-lactam and for the corresponding combination with avibactam (4 mg/L), which lacks direct antibacterial and enhancer activities. Secondly, Table 3 
MICs of meropenem and cefepime combined with DBOs
As would be expected, the great majority of MBL producers were resistant to unprotected meropenem and cefepime. Most, however, became susceptible to these agents when they were combined with 4 mg/L nacubactam (Table 2) . Thus, meropenem/nacubactam at 8!4 mg/L was active against 87.1% of the 210 Consecutive isolates, which provide the best representation of currently circulating MBL producers, while cefepime/nacubactam at 8!4 mg/L was active against 93.3% of these isolates. Corresponding proportions susceptible to meropenem/avibactam and cefepime/avibactam at 8!4 mg/L were much smaller, at 24.8% and 22.4%, respectively.
The wide activity of meropenem/nacubactam and cefepime/ nacubactam at 8!4 mg/L against E. coli and Enterobacter spp. was substantially attributable to the direct antibacterial activity of nacubactam against these species (see Table 1 ). However, meropenem/nacubactam at 8!4 mg/L and cefepime/nacubactam at Mushtaq et al. (Table 2) , whereas 4 mg/L nacubactam alone only inhibited only 40 (25.5%) of these isolates (Table 1 ). These gains in activity, relative to nacubactam alone, are best explained by the enhancer effect and are most clearly illustrated by data for the Combined Collection in Table 3 .
Overall, the addition of nacubactam at 1, 2 or 4 mg/L allowed meropenem at 8 mg/L to inhibit 53.7%, 80.9% and 84.8% of all MBL producers; corresponding proportions for equivalent cefepime combinations were 47.2%, 85.4% and 90.0%, respectively, whereas the proportions inhibited by nacubactam alone at 1, 2 or 4 mg/L were only 12.6%, 35.0% and 49.2%, respectively (Table 1) . Similarly large gains in activity compared with nacubactam alone were apparent when other prospective meropenem and cefepime breakpoints were considered, when the Consecutive Collection alone was considered or when only NDM Klebsiella spp. (as. the most populous group) were considered ( Table 3) .
In general, cefepime/nacubactam combinations inhibited a slightly larger proportion of MBL producers than the corresponding meropenem/nacubactam combinations when the nacubactam concentration was 2 or 4 mg/L whereas the position reversed, with meropenem/nacubactam more active, when the nacubactam concentration was 1 mg/L. The activity of meropenem/nacubactam and cefepime/nacubactam did not show any clear relationship to MBL type (IMP, NDM or VIM), nor to aztreonam susceptibility and resistance, which was taken as a proxy for whether or not ESBL or AmpC enzymes are co-produced (Table 2) .
Forty-seven isolates from the Combined Collection were resistant to meropenem/nacubactam at 8!4 mg/L. These comprised 30 Klebsiella spp., 9 Proteeae, 4 Citrobacter spp., 3 E. coli and 1 Enterobacter spp.; 36 had NDM MBLs, 9 had VIM and 2 had IMP. Although Klebsiella spp. and NDM dominated, it should be recalled that these were the most populous species (159 of 309, 51.5%) and MBL type (200 of 309, 64.7%) across the whole collection. The presence of 9 of 15 Proteeae and 4 of 10 Citrobacter spp. is more notable and underscores the frequent resistance to these groups to the antibacterial action of nacubactam ( Table 1 ). The synergy between meropenem and 4 mg/L nacubactam was often weak or absent for Proteeae, with meropenem MICs reduced 8-fold in only 1 of 15 cases; the synergy was greater with cefepime, where 8-fold MIC reductions were seen for 11 of 15 Proteeae.
MICs of aztreonam combined with DBOs
As noted earlier, aztreonam combinations differ from the others considered here insofar as they utilize a b-lactam that is not a substrate for MBLs, meaning that low MICs are to be anticipated so long as the inhibitor inactivates any co-produced monobactamhydrolysing ESBL or AmpC enzyme. 
Nacubactam combinations against nacubactamresistant isolates
Isolates that are resistant to the antibacterial activity of both nacubactam and its MBL-labile antibiotic partners are of particular interest, because low combination MICs here must depend upon the enhancer effect. 9,11 Accordingly, Table 4 shows the MIC distributions of nacubactam combinations, compared with unprotected b-lactams and avibactam combinations, for the 110 isolates for which the nacubactam MICs were .32 mg/L and for 57 of these that were highly resistant to meropenem and cefepime, with MICs 128 mg/L.
Nacubactam combinations retained activity against many of these difficult organisms. Thus, at 8!4 mg/L, meropenem/nacubactam inhibited 61.8% of all isolates that were resistant to nacubactam 
Conclusions
Along with boronates, DBOs are among the most promising newgeneration of b-lactamase inhibitors. 1 A limitation is that DBOs do not directly inhibit MBLs, which are a rising global problem, 6, 16 whereas some of these enzymes are inhibited by developmental boronates such as VNRX-5133 17 (VenatoRx), though not by vaborbactam, which is the sole licensed boronate analogue. Routes around this limitation are to combine the DBO with an MBL-stable monobactam, as with aztreonam/avibactam, 7, 8 or to use a tripleaction DBO, such as nacubactam or zidebactam. 3, 5, 9, 10 Although the direct antibacterial activity of triple action DBOs is vulnerable to high-frequency mutations that compensate for the inhibition of PBP2, 3, 9, 11, 12 these commonly leave a functional enhancer effect; moreover, DBO-resistant mutants grow as round forms under the DBO challenge, 9, 12 and the ability of these to sustain infection is questionable.
Despite utilizing MBL-labile b-lactams, both meropenem/nacubactam and cefepime/nacubactam achieved wide activity against MBL producers, independently of the MBL type and the isolates' aztreonam-resistance status. Activity did vary with species, with raised meropenem/nacubactam and cefepime/nacubactam MICs being more frequent among Proteeae. These are uncommon hosts for MBLs in most countries, 16, 18 though there are scattered reports, notably of Providencia spp. with NDM enzymes in Latin America. 19, 20 Meropenem/nacubactam or cefepime/nacubactam retained activity against many MBL producers that had high-level resistance to these molecules individually (Table 4 ). This behaviour is believed to reflect the enhancer effect, contingent on the simultaneous attack on PBP2 by nacubactam and PBP3 by the partner b-lactam. Although meropenem itself has a significant affinity for PBP2, it is not so primarily directed against this target as imipenem, and has a potent affinity for PBP3. 21, 22 Aztreonam/nacubactam (and aztreonam/avibactam) achieved wider activity against MBL-producing Enterobacteriaceae than meropenem/nacubactam or cefepime/nacubactam. However, their overall spectrum is narrower, owing to aztreonam having limited activity against Pseudomonas and none against Gram-positive genera or anaerobes. 23 Moreover, aztreonam, which targets only PBP3, is more weakly bactericidal than cephalosporins and carbapenems, which target multiple PBPs. On the other hand, some will consider a narrower spectrum to be ecologically preferable and note that aztreonam has the advantages of limited cross-allergenicity with other b-lactams and little selectivity for Clostridium difficile. 24, 25 The data presented here, coupled with the near universal activity of nacubactam combinations against isolates with non-metallo-carbapenemases 3, 9 support the progression of nacubactam combinations into clinical development.
